About this trial
The investigators plan to use artificial intelligence to analyse vaginal ultrasound images of the uterine lining (endometrium) taken during routine IVF treatment, which may predict implantation success during IVF treatment.
Participation in the study is voluntary, involves no additional testing or intervention beyond routine procedures, and consent can be withdrawn verbally or in writing at any time without cause or adverse consequences.
Over a three-year period, the trial is expected to enrol approximately 1,500 patients between the ages of 18 and 40 who are indicated for IVF treatment and who volunteer for treatment.
Patients enrolled in the study will not be required to attend more clinic visits during treatment than they would otherwise have to. During the trial, certain patient-specific data (age, indication for treatment, body mass index), stimulation-specific data (duration of stimulation, type and dose of drug, endometrial thickness), ultrasound scans and outcome-specific data (treatment failure, biochemical pregnancy, clinical pregnancy) will be collected. The data will be stored in a secure database. The data collected during the study will only be accessible to the professionals involved in the study and no information, including personal data, will be disclosed to third parties.
Eligibility criteria
Qualifiers
Female patient 18-40 years, for whom IVF is indicated
Maximum 3 unsuccessful previous embryo transfers
Only cycles in which single blastocyst is transferred
Disqualifiers
Congenital uterine anomalies, fibroids, adenomyosis, Asherman-syndrome or any other conditions resulting in malformation of the uterus
Presence of hydrosalpinx
Endometriosis
Planned freeze-all cycle
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Gottsegen National Cardiovascular Institute
Lead sponsor
Dunamenti REK Reprodukcios Kozpont
Collaborator